Playing tag with HIF: The VHL story

Journal of Biomedicine and Biotechnology

Volumn 2002, Issue 3, 2002, Pages 131-135

  Leung, Sherri K ^a   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; CULLIN 2 ENZYME; ELONGIN BC; HYPOXIA INDUCIBLE FACTOR 1; MULTIPROTEIN COMPLEX; RING BOX PROTEIN 1 ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN; VEC ENZYME; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL INVASION; COMPLEX FORMATION; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; GENE INACTIVATION; GENE TARGETING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INHERITANCE; KIDNEY CANCER; MICROENVIRONMENT; MOLECULAR CLONING; PH MEASUREMENT; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE; UBIQUITINATION; VON HIPPEL LINDAU DISEASE;

EID: 25144512803     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/S1110724302205057     Document Type: Review

References (38)

1. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore). 1997;76(6):381-391.
2. Ohh M, Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today. 1999;5(6):257-263.
3. Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med. 1998;243(6):527-533.
4. Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA. 1988;85(5):1571-1575.
5. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327(6124):721- 724.
6. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301(11):592-595.
7. Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer. 1989;43(3):422-127.
8. Pathak S, Strong LC, Ferrell RE, Trindade A. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science. 1982;217(4563):939-941.
9. Seizinger BR, Rouleau GA, Ozelius LJ, et al. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332(6161):268-269.
10. Richards FM, Maher ER, Latif F, et al. Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene. J Med Genet. 1993;30(2):104-107.
11. Yao M, Latif F, Orcutt ML, et al. von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet. 1993;92(6):605-614.
12. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-1320.
13. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5(1):66-75.
14. Ivan M, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001;11(1):27-34.
15. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284(5413):455-461.
16. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA. 2001;98(4):1583-1588.
17. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA. 1997;94(17):9102-9107.
18. Semenza GL. Perspectives on oxygen sensing. Cell 1999;98(3):281-284.
19. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001;107(1):1-3.
20. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275.
21. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733-25741.
22. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2(7):423-427.
23. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19(16):4298-4309.
24. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468.
25. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472.
26. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001;20(18):5197-5206.
27. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43-54.
28. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340.
29. Hochstrasser M. Evolution and function of ubiquitin-like protein-conjugation systems. Nat Cell Biol. 2000;2(8):E153-E157.
30. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays. 2000;22(5):442-451.
31. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999;15:435-467.
32. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem. 1999;274(17):12036-12042.
33. Liakopoulos D, Doenges G, Matuschewski K, Jentsch S. A novel protein modification pathway related to the ubiquitin system. EMBO J. 1998;17(8):2208-2214.
34. Ohh M, Kim WY, Moslehi JJ, et al. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 2002;3(2):177-182.
35. Podust VN, Brownell JE, Gladysheva TB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA. 2000;97(9):4579-4584.
36. βTrCP-dependent ubiquitination of IκBα. Mol Cell Biol: 2000;20(7):2326-2333.
37. Kawakami T, Chiba T, Suzuki T, et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 2001;20(15):4003-4012.
38. Semenza GL. HIF-I and human disease: one highly involved factor. Genes Dev. 2000;14(16):1983-1991.